Home > D. Systemic pathology > Toxics and drugs > Therapeutics > Targeted therapy > Small molecules > bosutinib

bosutinib

Tuesday 10 June 2014

WKP

Bosutinib (rINN/USAN; codenamed SKI-606, marketed under the trade name Bosulif) is a tyrosine kinase inhibitor (TKI) undergoing research for use in the treatment of cancer.

Originally synthesized by Wyeth, it is being developed by Pfizer.

Open references

- Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia. Rassi FE, Khoury HJ. Pharmgenomics Pers Med. 2013 Aug 5;6:57-62. PMID: 24019749